X Biotech Inc. XBIT
We take great care to ensure that the data presented and summarized in this overview for XBiotech Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding XBIT
View all-
Black Rock Inc. New York, NY1.13MShares$7.55 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.06MShares$7.07 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA452KShares$3.01 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny281KShares$1.87 Million0.0% of portfolio
-
Ubs Asset Management Americas Inc Chicago, IL254KShares$1.69 Million0.0% of portfolio
-
Credit Suisse Ag Zurich, V8248KShares$1.65 Million0.0% of portfolio
-
State Street Corp Boston, MA225KShares$1.5 Million0.0% of portfolio
-
Northern Trust Corp Chicago, IL184KShares$1.22 Million0.0% of portfolio
-
Bridgeway Capital Management, LLC Houston, TX148KShares$982,9620.03% of portfolio
-
Morgan Stanley New York, NY132KShares$877,0480.0% of portfolio
Latest Institutional Activity in XBIT
Top Purchases
Top Sells
About XBIT
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation, and True Human COVID-19 therapy for treating the COVID-19 mutant virus. The company was incorporated in 2005 and is headquartered in Austin, Texas.
Insider Transactions at XBIT
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 16
2021
|
W Thorpe Mckenzie |
SELL
Payment of exercise price or tax liability
|
Direct |
213,493
-7.6%
|
$2,348,423
$11.71 P/Share
|
|
Dec 16
2021
|
W Thorpe Mckenzie |
BUY
Exercise of conversion of derivative security
|
Direct |
250,000
+8.17%
|
$2,500,000
$10.0 P/Share
|
|
Oct 18
2021
|
John Simard Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
33,000
-0.86%
|
$429,000
$13.07 P/Share
|
|
Oct 15
2021
|
John Simard Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
17,000
-0.44%
|
$221,000
$13.32 P/Share
|
|
Oct 14
2021
|
John Simard Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
21,125
-0.54%
|
$253,500
$12.9 P/Share
|
|
Oct 13
2021
|
John Simard Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
10,875
-0.27%
|
$130,500
$12.83 P/Share
|
|
Oct 12
2021
|
John Simard Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
18,000
-0.45%
|
$216,000
$12.77 P/Share
|
|
Oct 07
2021
|
John Simard Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
39,286
-0.99%
|
$471,432
$12.45 P/Share
|
|
Oct 06
2021
|
John Simard Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
10,714
-0.27%
|
$128,568
$12.53 P/Share
|
|
Oct 05
2021
|
John Simard Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
14,218
-0.36%
|
$170,616
$12.66 P/Share
|
|
Oct 04
2021
|
John Simard Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
23,681
-0.59%
|
$307,853
$13.08 P/Share
|
|
Oct 01
2021
|
John Simard Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
19,684
-0.49%
|
$255,892
$13.23 P/Share
|
|
Sep 30
2021
|
John Simard Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
18,558
-0.46%
|
$241,254
$13.07 P/Share
|
|
Sep 29
2021
|
John Simard Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
16,396
-0.4%
|
$213,148
$13.41 P/Share
|
|
Sep 28
2021
|
John Simard Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
6,263
-0.15%
|
$87,682
$14.27 P/Share
|
|
Sep 27
2021
|
John Simard Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
29,890
-0.73%
|
$418,460
$14.81 P/Share
|
|
Sep 24
2021
|
John Simard Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
11,418
-0.28%
|
$159,852
$14.49 P/Share
|
|
Sep 23
2021
|
John Simard Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
9,892
-0.24%
|
$138,488
$14.68 P/Share
|
|
Sep 22
2021
|
John Simard Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
19,669
-0.47%
|
$295,035
$15.14 P/Share
|
|
Sep 21
2021
|
John Simard Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
16,860
-0.41%
|
$252,900
$15.24 P/Share
|